Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital LLC, effective October 28, 2026. The agreement allowed the company to sell up to $6.0 million of common stock at its discretion based on market price. No early termination penalty is payable. Allarity will not issue additional shares under this deal and plans to pursue alternative financing arrangements. The company operates in the biotechnology sector, focusing on drug discovery.
